Sign In
Section Navigation
Common TitleSWITCHMRK 1 and 2
Official Title A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of Raltegravir (MK0518) Versus KALETRA in HIV-Infected Patients Switched From a Stable KALETRA-Based Regimen - Study A and Study B
Phase Phase III
ClinicalTrials.gov NCT00443703
Treatments
Raltegravir
Raltegravir Isentress

Raltegravir

Tradename:IsentressOther Names:RALClass:Integrase Strand Transfer Inhibitors (INSTI)
Categories Treatment-ExperiencedSwitch/Simplification
Funding
IndustryMerck Sharp & Dohme Corp
References
  • Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomized controlled trials. Lancet 2010; 375:396-407.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.